HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a report released on Thursday, Benzinga reports. HC Wainwright currently has a $37.00 price target on the stock.
Pharming Group Price Performance
Shares of PHAR stock traded up $0.42 during trading hours on Thursday, hitting $8.72. 2,626 shares of the company’s stock were exchanged, compared to its average volume of 4,869. The company has a market capitalization of $591.48 million, a PE ratio of -45.89 and a beta of 0.15. Pharming Group has a 12-month low of $6.65 and a 12-month high of $13.20. The business’s 50 day simple moving average is $8.03 and its 200-day simple moving average is $8.56. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40.
Pharming Group (NASDAQ:PHAR – Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The business had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same period in the prior year, the business posted $0.02 EPS. On average, equities research analysts anticipate that Pharming Group will post -0.15 earnings per share for the current year.
Hedge Funds Weigh In On Pharming Group
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
- Five stocks we like better than Pharming Group
- Stock Market Upgrades: What Are They?
- Texas Roadhouse Stock Steering for New Highs This Year
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is the Euro STOXX 50 Index?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.